Document is current
Any future updates will be listed below
-
Authors
Wang, Xin Shelley
Shi, Qiuling
Mendoza, Tito R.
Garcia-Gonzalez, Araceli
Chen, Ting-Yu
Kamal, Mona
Chen, Tsun Hsuan
Heijnen, Cobi
Orlowski, Robert Z.
Cleeland, Charles S.
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30CA016672, P01 CA124787)
- License Information
-
More Information
Article History
Received: 13 October 2020
Accepted: 24 February 2021
First Online: 1 April 2021
Declaration
:
: The study was approved by the IRB committee at MD Anderson Cancer Center.
: Written informed consent was signed by all patients.
: All patients gave consent with respect to the publication of the data collected as a part of the study.
: The authors have no competing financial interests to declare. RZO declares laboratory research funding from BioTheryX and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and as a consultant for STATinMED Research. Finally, RZO is a Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current manuscript.
